A lawyer for the U.S. Chamber of Commerce on Friday urged a federal judge to block President Joe Biden's administration from implementing a new program that would let Medicare negotiate prices with ...
WASHINGTON — Attorneys for the U.S. Chamber of Commerce and the federal government sparred Friday over whether drugmakers have enough say in Medicare’s new drug price negotiation program, in ...
The Chamber of Commerce urged a federal judge on Friday to stop the new Medicare drug price negotiation program before Oct. 1 ...
The manufacturers of the 10 initial drugs chosen for Medicare’s price negotiation program have agreed to participate in the ...
Manufacturers of 10 drugs selected for Medicare price negotiation have signed agreements to participate in the program under ...
All of the companies had drugs that made the list of the first 10 medications to be subject to Medicare price negotiations. PhRMA, a leading drug industry trade group, and the US Chamber of ...
The Shutdown Will Be as Painful as Biden Wants It to Be Something Is Going to Break Fixing the prices of prescription drugs creates shortages and stifles research into new drugs. Are the laws of ...
The Biden administration will face the first major legal test of its new Medicare drug pricing authority on Friday, when a federal judge in Ohio hears oral arguments in the first of a wave of ...
As we have covered in previous articles here, the new authority Congress provided to the Department of Health and Human Services (HHS) under the Inflation Reduction Act (IRA) to directly negotiate ...
Share on Facebook. Opens in a new tab or window Share on Twitter. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Experts debated the claims made by drug companies and ...
Sept 15 (Reuters) - A lawyer for the U.S. Chamber of Commerce on Friday urged a federal judge to block President Joe Biden's administration from implementing a new program that would let Medicare ...
Japanese drugmaker Astellas (OTCPK:ALPMF) has withdrawn a federal lawsuit that challenged the US government’s right to negotiate drug prices for its Medicare program, but maintained the newly ...
